Table 2.

Neurotherapeutic Strategies for Lung Cancer

Therapy type	Drug	Treatment Pathway	Clinical Status	references
Beta-blockers	Propranolol	Beta-adrenergic signaling, reduces tumor growth	NCT00409968 NCT00949650	[204, 205]
α2-Adrenergic receptor agonists	Prazosin	Increases oxidative stress, reduces tumor viability	/	[221, 222]
Dopamine receptor antagonist	Quetiapine	Inactivates ERK/AKT pathways, induces apoptosis	/	[136, 138]
Partial agonist of acetylcholine receptors	cytisine	Preventing lung cancer through smoking cessation therapy	NCT03654105	[233]
Acetylcholine receptor antagonist	Dafinacin	By blocking the YAP-ChAT-ACh-M3R-WNT signaling axis to reverse EGFR-TKI resistance	/	[190]
Glutamate receptor antagonist	Memantine	Inhibit tumor growth	/	[180, 181]
SSRI	Fluoxetine	Inhibits ERK/NF-κB signaling, induces apoptosis	NCT00005850	[122]
SNRI	Duloxetine	Enhances caspase activity, induces apoptosis	/	[231]
Thymosin	Thymalfasin	Monotherapy + Combination Therapy. Inhibition of the STAT3/MMP2 pathway.	/	[230]
TMEM16A inhibitor	cryptochlorogenic acid(CCA)	Inhibiting TMEM16A ion channel activity to regulate MAPK and EMT pathways	/	[232]